Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 ...

Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and ...